35Pharma Announces Oral Presentation of HS235 Pre-Clinical Data in Models of Pulmonary Hypertension at ERS 2025

35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today presented HS235 pre-clinical data during an oral presentation at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands (Sep 27-Oct 1, 2025).

‍

‍

HS235 is a next-generation Activin Signaling Inhibitor under investigation in Phase 1b/2a trials in patients with pulmonary hypertension (PH) (NCT07143448, NCT07123779). HS235 was engineered to spare BMP-9/-10, whose inhibition has been associated with bleeding, telangiectasia and pericardial effusions in both pre-clinical and clinical settings. In addition, HS235 was designed for greater potency against Activin and Growth Differentiation Factor ligands compared to previous generation agents. HS235’s novel neutralization profile is expected to result in superior safety, efficacy, and cardiometabolic benefits.

‍

During an oral presentation at ERS 2025, 35Pharma Chief Scientific Officer Maureen O’Connor shared pre-clinical data with HS235 supporting its pulmonary and cardiac activity in murine models of pulmonary hypertension and heart failure.

‍

Highlights of the presentation included:

‍

• In a murine transverse aortic constriction (TAC) model of Group 2 PH, HS235
  • Reverse remodeled pulmonary vasculature and improved right ventricular function
  • Rescued left ventricular function and normalised levels of NT-proBNP, a validated biomarker of heart failure
• In a murine model of obese Heart Failure with preserved Ejection Fraction (HFpEF), HS235
  • Rescued left ventricular function
  • Reduced fat and increased lean muscle mass
  • Returned exercise capacity to the levels of lean controls